Categories
Loading...
Categories
Venmax Drugs & Pharmaceuticals confirmed no deviation in using funds from its preferential issue of fully convertible equity warrants. The company intended to raise Rs. 20.05 crore, having received Rs. 14.53 crore. These funds were allocated for working capital and general corporate purposes, with Rs. 8.12 crore utilized for working capital and Rs. 0.20 crore for general corporate purposes. This confirmation, reviewed by the Audit Committee, assures shareholders that capital is deployed as originally planned, reflecting transparent financial management.